Major Win for Sanofi: Rezurock Gets EU Green Light for Chronic GVHD
Sanofi (SNY) has received conditional marketing authorization from the European Union for its therapeutic agent, Rezurock. This approval covers the use of Rezu…
Sanofi (SNY) has received conditional marketing authorization from the European Union for its therapeutic agent, Rezurock. This approval covers the use of Rezurock for the treatment of chronic graft-versus-host disease (GVHD) in adult patients and adolescents aged 12 years and older.
Sanofi (SNY) currently holds an RS Score of 75.10, placing it in the 71.30th percentile within its country and sector. The stock demonstrates particular strength in its Valuation and EPS Revisions sections, scoring 95.88 and 95.00 respectively. Conversely, areas such as Growth (21.61), Profitability (4.46), and Momentum (70.00) appear weaker. Want to discover which stocks rank the highest? Start your free 7-day trial at rankedstocks.com.